Document
P30Dfalse--05-31Q220190001275187falseAccelerated FilerANGIODYNAMICS INCfalseANGO246600022250001.000.050.660.040.950.900.010.01750000007500000037594493378755293722449337505529P15YP7YP5YP2Y40000410000.010.01500000050000000000P3Y370000370000 0001275187 2018-06-01 2018-11-30 0001275187 2019-01-03 0001275187 2017-06-01 2017-11-30 0001275187 2018-09-01 2018-11-30 0001275187 2017-09-01 2017-11-30 0001275187 2018-11-30 0001275187 2018-05-31 0001275187 2017-05-31 0001275187 2017-11-30 0001275187 us-gaap:CommonStockMember 2018-06-01 2018-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2018-09-01 2018-11-30 0001275187 us-gaap:RetainedEarningsMember 2018-06-01 2018-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2018-08-31 0001275187 us-gaap:CommonStockMember 2018-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2018-06-01 2018-08-31 0001275187 us-gaap:TreasuryStockMember 2018-11-30 0001275187 us-gaap:TreasuryStockMember 2018-05-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2018-06-01 2018-08-31 0001275187 2018-06-01 2018-08-31 0001275187 us-gaap:TreasuryStockMember 2018-08-31 0001275187 us-gaap:RetainedEarningsMember 2018-08-31 0001275187 us-gaap:CommonStockMember 2018-05-31 0001275187 us-gaap:CommonStockMember 2018-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2018-09-01 2018-11-30 0001275187 us-gaap:PerformanceSharesMember 2018-09-01 2018-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember 2018-06-01 2018-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-05-31 0001275187 us-gaap:RetainedEarningsMember 2018-11-30 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2018-06-01 2018-08-31 0001275187 us-gaap:PerformanceSharesMember us-gaap:CommonStockMember 2018-06-01 2018-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-08-31 0001275187 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2018-09-01 2018-11-30 0001275187 us-gaap:CommonStockMember 2018-09-01 2018-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-01 2018-11-30 0001275187 us-gaap:AdditionalPaidInCapitalMember 2018-05-31 0001275187 us-gaap:RetainedEarningsMember 2018-05-31 0001275187 us-gaap:PerformanceSharesMember 2018-06-01 2018-08-31 0001275187 us-gaap:RetainedEarningsMember 2018-09-01 2018-11-30 0001275187 2018-08-31 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-01 2018-08-31 0001275187 us-gaap:AdditionalPaidInCapitalMember 2018-11-30 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 ango:RadiaDyneMember 2018-09-21 0001275187 ango:RadiaDyneMember ango:RevenueBasedPaymentMember 2018-09-21 0001275187 ango:RadiaDyneMember ango:TechnicalMilestonesMember 2018-09-21 0001275187 ango:RadiaDyneMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-08-14 2018-08-14 0001275187 ango:BioSentryMember 2018-06-01 2018-11-30 0001275187 ango:BioSentryMember 2018-08-14 2018-08-14 0001275187 ango:RadiaDyneMember 2018-06-01 2018-11-30 0001275187 srt:MaximumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember 2018-08-14 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember 2018-08-15 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-08-14 0001275187 ango:BioSentryMember 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-11-30 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-08-15 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-08-14 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-08-14 0001275187 ango:BioSentryMember us-gaap:CustomerRelationshipsMember 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-08-15 2018-11-30 0001275187 ango:BioSentryMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-08-15 2018-11-30 0001275187 ango:RadiaDyneMember ango:RadiaDyneTechnologyBasedIntangibleAssetsMember 2018-09-21 0001275187 ango:RadiaDyneMember ango:RadiaDyneTrademarkMember 2018-09-21 0001275187 ango:RadiaDyneMember ango:OarTracTechnologyBasedIntangibleAssetsMember 2018-09-21 0001275187 ango:RadiaDyneMember ango:OarTracTrademarkMember 2018-09-21 0001275187 ango:RadiaDyneMember us-gaap:CustomerRelationshipsMember 2018-09-21 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TrademarksMember 2018-09-21 2018-09-21 0001275187 srt:MinimumMember ango:RadiaDyneMember us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-21 2018-09-21 0001275187 ango:BioSentryMember us-gaap:TrademarksMember 2018-08-14 2018-08-14 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2018-06-01 2018-11-30 0001275187 ango:VascularAccessMember 2018-06-01 2018-11-30 0001275187 ango:VascularAccessMember country:US 2018-06-01 2018-11-30 0001275187 us-gaap:NonUsMember 2018-06-01 2018-11-30 0001275187 country:US 2018-06-01 2018-11-30 0001275187 ango:OncologyMember 2018-06-01 2018-11-30 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2018-06-01 2018-11-30 0001275187 ango:VascularInterventionsandTherapiesMember 2018-06-01 2018-11-30 0001275187 ango:OncologyMember us-gaap:NonUsMember 2018-06-01 2018-11-30 0001275187 ango:OncologyMember country:US 2018-06-01 2018-11-30 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2018-06-01 2018-11-30 0001275187 ango:OncologyMember us-gaap:NonUsMember 2018-09-01 2018-11-30 0001275187 ango:OncologyMember country:US 2018-09-01 2018-11-30 0001275187 ango:VascularInterventionsandTherapiesMember country:US 2018-09-01 2018-11-30 0001275187 ango:VascularAccessMember us-gaap:NonUsMember 2018-09-01 2018-11-30 0001275187 ango:VascularInterventionsandTherapiesMember 2018-09-01 2018-11-30 0001275187 ango:VascularAccessMember country:US 2018-09-01 2018-11-30 0001275187 ango:VascularInterventionsandTherapiesMember us-gaap:NonUsMember 2018-09-01 2018-11-30 0001275187 ango:OncologyMember 2018-09-01 2018-11-30 0001275187 country:US 2018-09-01 2018-11-30 0001275187 ango:VascularAccessMember 2018-09-01 2018-11-30 0001275187 us-gaap:NonUsMember 2018-09-01 2018-11-30 0001275187 srt:MaximumMember 2018-06-01 2018-11-30 0001275187 srt:MinimumMember 2018-06-01 2018-11-30 0001275187 ango:AcculisInventoryMember 2018-11-30 0001275187 ango:AcculisInventoryMember 2018-05-31 0001275187 ango:ProductTechnologiesMember 2018-11-30 0001275187 us-gaap:TrademarksMember 2018-11-30 0001275187 ango:DistributorRelationshipsMember 2018-11-30 0001275187 us-gaap:CustomerRelationshipsMember 2018-11-30 0001275187 us-gaap:LicenseAgreementTermsMember 2018-11-30 0001275187 us-gaap:TrademarksMember 2018-05-31 0001275187 ango:ProductTechnologiesMember 2018-05-31 0001275187 us-gaap:CustomerRelationshipsMember 2018-05-31 0001275187 us-gaap:LicenseAgreementTermsMember 2018-05-31 0001275187 ango:DistributorRelationshipsMember 2018-05-31 0001275187 2017-12-31 2017-12-31 0001275187 srt:MaximumMember 2016-06-01 2017-05-31 0001275187 us-gaap:SecuredDebtMember us-gaap:LineOfCreditMember 2018-11-30 0001275187 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-11-30 0001275187 us-gaap:LetterOfCreditMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 0001275187 us-gaap:SecuredDebtMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 0001275187 us-gaap:BridgeLoanMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 2016-11-07 0001275187 ango:FormerCreditAgreementMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 2016-11-07 0001275187 ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2018-11-30 0001275187 us-gaap:SecuredDebtMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 2016-11-07 0001275187 us-gaap:RevolvingCreditFacilityMember ango:JPMorganChaseBankN.A.BankofAmericaN.A.KeybankNationalAssociationMember us-gaap:LineOfCreditMember 2016-11-07 0001275187 ango:The2004PlanandEmployeeStockPurchasePlanMember 2018-11-30 0001275187 us-gaap:PerformanceSharesMember 2018-06-01 2018-11-30 0001275187 ango:VascularAccessMember 2017-09-01 2017-11-30 0001275187 ango:OncologyMember 2017-09-01 2017-11-30 0001275187 ango:OncologyMember 2017-06-01 2017-11-30 0001275187 ango:VascularAccessMember 2017-06-01 2017-11-30 0001275187 ango:VascularInterventionsandTherapiesMember 2017-09-01 2017-11-30 0001275187 ango:VascularInterventionsandTherapiesMember 2017-06-01 2017-11-30 0001275187 us-gaap:NonUsMember 2017-06-01 2017-11-30 0001275187 country:US 2017-09-01 2017-11-30 0001275187 country:US 2017-06-01 2017-11-30 0001275187 us-gaap:NonUsMember 2017-09-01 2017-11-30 0001275187 ango:SupplierDefaultHoldbackPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:ValuationTechniqueEstimatedProbabilityMember 2018-11-30 0001275187 ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2018-11-30 0001275187 us-gaap:FairValueInputsLevel3Member ango:ContingentConsiderationEarnOutLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0001275187 ango:TechnicalMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:ValuationTechniqueEstimatedProbabilityMember 2018-11-30 0001275187 srt:MaximumMember 2018-11-30 0001275187 srt:MinimumMember 2018-11-30 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2018-05-31 0001275187 us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-05-31 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-05-31 0001275187 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-05-31 0001275187 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0001275187 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-11-30 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2018-11-30 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2018-11-30 0001275187 srt:MinimumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2018-11-30 0001275187 srt:MaximumMember ango:RevenueBasedPaymentMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ango:MeasurementInputProbabilityofPaymentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2018-11-30 0001275187 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-11-30 0001275187 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-05-31 0001275187 ango:TheUtahActionMember 2016-03-24 2016-03-24 0001275187 ango:TheUtahActionMember 2016-03-11 2016-03-11 0001275187 ango:TheUtahActionMember 2016-03-29 2016-03-29 0001275187 ango:ConstructionIssuesMember 2018-11-30 0001275187 ango:TheUtahActionMember us-gaap:PendingLitigationMember 2016-03-30 2017-01-31 0001275187 ango:TheUtahActionMember 2016-03-24 0001275187 ango:TheDelawareActionMember 2015-03-10 2015-03-10 0001275187 ango:CrBardIncMember 2012-01-11 2012-01-11 0001275187 ango:TheUtahActionMember 2016-03-11 0001275187 ango:TheUtahActionMember 2012-01-11 2012-01-11 0001275187 2018-07-01 2018-07-31 0001275187 ango:C.R.BardInc.Member ango:TheUtahActionMember us-gaap:PendingLitigationMember 2016-03-30 2017-01-31 0001275187 ango:TheDelawareActionMember 2015-06-01 2015-06-01 0001275187 ango:CrBardIncMember 2018-06-01 2018-11-30 0001275187 us-gaap:RestructuringChargesMember 2018-09-01 2018-11-30 0001275187 ango:LegalCostsMember 2017-06-01 2017-11-30 0001275187 us-gaap:RestructuringChargesMember 2017-09-01 2017-11-30 0001275187 ango:MergersandAcquisitionsMember 2018-09-01 2018-11-30 0001275187 ango:LegalCostsMember 2018-06-01 2018-11-30 0001275187 ango:LegalCostsMember 2018-09-01 2018-11-30 0001275187 us-gaap:OtherExpenseMember 2018-06-01 2018-11-30 0001275187 us-gaap:OtherExpenseMember 2017-09-01 2017-11-30 0001275187 ango:MergersandAcquisitionsMember 2017-09-01 2017-11-30 0001275187 us-gaap:OtherExpenseMember 2018-09-01 2018-11-30 0001275187 us-gaap:RestructuringChargesMember 2018-06-01 2018-11-30 0001275187 ango:MergersandAcquisitionsMember 2017-06-01 2017-11-30 0001275187 ango:MergersandAcquisitionsMember 2018-06-01 2018-11-30 0001275187 ango:LegalCostsMember 2017-09-01 2017-11-30 0001275187 us-gaap:RestructuringChargesMember 2017-06-01 2017-11-30 0001275187 us-gaap:OtherExpenseMember 2017-06-01 2017-11-30 0001275187 ango:RegulatoryFilingsMember 2018-11-30 0001275187 ango:EquipmentTransferMember 2018-11-30 0001275187 ango:EquipmentTransferMember 2018-06-01 2018-11-30 0001275187 us-gaap:OneTimeTerminationBenefitsMember 2018-05-31 0001275187 us-gaap:ContractTerminationMember 2018-06-01 2018-11-30 0001275187 us-gaap:ContractTerminationMember 2018-05-31 0001275187 us-gaap:OneTimeTerminationBenefitsMember 2018-06-01 2018-11-30 0001275187 ango:EquipmentTransferMember 2018-05-31 0001275187 ango:RegulatoryFilingsMember 2018-06-01 2018-11-30 0001275187 us-gaap:OneTimeTerminationBenefitsMember 2018-11-30 0001275187 ango:RegulatoryFilingsMember 2018-05-31 0001275187 us-gaap:ContractTerminationMember 2018-11-30 0001275187 ango:EquipmentTransferMember 2018-08-31 0001275187 us-gaap:ContractTerminationMember 2018-08-31 0001275187 ango:RegulatoryFilingsMember 2018-09-01 2018-11-30 0001275187 us-gaap:OneTimeTerminationBenefitsMember 2018-09-01 2018-11-30 0001275187 us-gaap:ContractTerminationMember 2018-09-01 2018-11-30 0001275187 us-gaap:OneTimeTerminationBenefitsMember 2018-08-31 0001275187 ango:RegulatoryFilingsMember 2018-08-31 0001275187 ango:EquipmentTransferMember 2018-09-01 2018-11-30 0001275187 2017-02-01 2018-11-30 0001275187 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-01 2018-11-30 0001275187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-30 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2018-11-30 0001275187 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-11-30 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-01 2018-11-30 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2017-11-30 0001275187 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-11-30 0001275187 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-01 2018-11-30 0001275187 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-05-31 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-01 2018-11-30 0001275187 us-gaap:AccumulatedTranslationAdjustmentMember 2018-05-31 xbrli:pure ango:segment ango:motion ango:Petition iso4217:USD xbrli:shares iso4217:USD ango:claim ango:patent xbrli:shares ango:reexamination_appeal ango:Investment
Table of Contents

    
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended November 30, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 0-50761

 
AngioDynamics, Inc.
(Exact name of registrant as specified in its charter)
http://api.tenkwizard.com/cgi/image?quest=1&rid=23&ipage=12630032&doc=11
 
 

Delaware
 
11-3146460
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
14 Plaza Drive Latham, New York
 
12110
(Address of principal executive offices)
 
(Zip Code)
(518) 795-1400
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Name of each exchange on which registered
Common stock, par value $.01
 
NASDAQ Global Select Market
Preferred Stock Purchase Rights
 
NASDAQ Global Select Market
Securities registered pursuant to Section 12(g) of the Act:


Table of Contents

None
(Title of Class)
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ¨    No  x
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
  
Accelerated filer
 
x
 
 
 
 
Non-accelerated filer
 
¨
  
Smaller reporting company
 
¨
 
 
 
 
 
 
 
Emerging growth company
 
o
 
 
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date.
Class
 
Outstanding as of January 3, 2019
Common Stock, par value $.01
 
37,137,203
 



Table of Contents

AngioDynamics, Inc. and Subsidiaries
TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
 
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
Item 5.
 
 
 
Item 6.

2

Table of Contents

PART 1. FINANCIAL INFORMATION
Item 1. Financial Statements.

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands of dollars, except per share data)
 
 
 
Three Months Ended
 
Six Months Ended
 
 
Nov 30, 2018
 
Nov 30, 2017
 
Nov 30, 2018
 
Nov 30, 2017
Net sales
 
$
91,503

 
$
86,706

 
$
176,843

 
$
172,117

Cost of sales (exclusive of intangible amortization)
 
42,394

 
43,975

 
83,267

 
88,157

Gross profit
 
49,109

 
42,731

 
93,576

 
83,960

Operating expenses:
 
 
 
 
 
 
 
 
Research and development
 
7,363

 
6,107

 
15,025

 
12,548

Sales and marketing
 
20,269

 
18,967

 
39,702

 
38,369

General and administrative
 
9,336

 
7,540

 
17,832

 
15,596

Amortization of intangibles
 
5,188

 
4,146

 
9,304

 
8,242

Change in fair value of contingent consideration
 
244

 
82

 
256

 
187

Acquisition, restructuring and other items, net
 
2,728

 
4,766

 
7,150

 
7,755

Total operating expenses
 
45,128

 
41,608

 
89,269

 
82,697

Operating income
 
3,981

 
1,123

 
4,307

 
1,263

Other (expenses) income:
 
 
 
 
 
 
 
 
Interest expense, net
 
(1,330
)
 
(760
)
 
(2,247
)
 
(1,483
)
Other income (loss), net
 
80

 
(280
)
 
194

 
287

Total other expenses, net
 
(1,250
)
 
(1,040
)
 
(2,053
)
 
(1,196
)
Income before income tax expense
 
2,731

 
83

 
2,254

 
67

Income tax expense (benefit)
 
591

 
(166
)
 
583

 
(147
)
Net income
 
$
2,140

 
$
249

 
$
1,671

 
$
214

Earnings per share
 
 
 
 
 
 
 
 
Basic
 
$
0.06

 
$
0.01

 
$
0.04

 
$
0.01

Diluted
 
$
0.06

 
$
0.01

 
$
0.04

 
$
0.01

Weighted average shares outstanding
 
 
 
 
 
 
 
 
Basic
 
37,500

 
37,066

 
37,411

 
36,983

Diluted
 
38,117

 
37,383

 
38,131

 
37,322

The accompanying notes are an integral part of these consolidated financial statements.

3

Table of Contents

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)
(in thousands of dollars)
 
 
 
Three Months Ended
 
Six Months Ended
 
 
Nov 30, 2018
 
Nov 30, 2017
 
Nov 30, 2018
 
Nov 30, 2017
Net income
 
$
2,140

 
$
249

 
$
1,671

 
$
214

Other comprehensive income, before tax:
 
 
 
 
 
 
 
 
Unrealized gain on marketable securities
 

 
45

 
33

 
45

Foreign currency translation
 
(206
)
 
150

 
(331
)
 
433

Other comprehensive income (loss), before tax
 
(206
)
 
195

 
(298
)
 
478

Income tax expense related to items of other comprehensive income
 

 

 

 

Other comprehensive income (loss), net of tax
 
(206
)
 
195

 
(298
)
 
478

Total comprehensive income, net of tax
 
$
1,934

 
$
444

 
$
1,373

 
$
692

The accompanying notes are an integral part of these consolidated financial statements.


4

Table of Contents

AngioDynamics, Inc. and Subsidiaries

CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands of dollars, except share data)
 
Nov 30, 2018
 
May 31, 2018
Assets
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
42,820

 
$
74,096

Marketable securities
1,350

 
1,317

Accounts receivable, net of allowances of $2,225 and $2,466, respectively
43,374

 
39,401

Inventories
50,637

 
48,916

Prepaid expenses and other
4,776

 
4,302

Total current assets
142,957

 
168,032

Property, plant and equipment, net
41,945

 
42,461

Other assets
3,478

 
3,417

Intangible assets, net
168,706

 
130,310

Goodwill
426,874

 
361,252

Total assets
$
783,960

 
$
705,472

Liabilities and stockholders' equity
 
 
 
Current liabilities
 
 
 
Accounts payable
$
19,424

 
$
15,775

Accrued liabilities
21,272

 
34,426

Current portion of long-term debt
5,000

 
5,000

Current portion of contingent consideration
4,006

 
2,100

Total current liabilities
49,702

 
57,301

Long-term debt, net of current portion
139,266

 
86,621

Deferred income taxes
17,696

 
17,173

Contingent consideration, net of current portion
22,512

 
1,161

Other long-term liabilities
5,221

 
621

Total liabilities
234,397

 
162,877

Commitments and contingencies (Note 14)

 

Stockholders' equity
 
 
 
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, par value $.01 per share, 75,000,000 shares authorized; 37,875,529 and 37,594,493 shares issued and 37,505,529 and 37,224,493 shares outstanding at November 30, 2018 and May 31, 2018, respectively
372

 
370

Additional paid-in capital
549,355

 
543,762

Retained earnings
6,800

 
5,129

Treasury stock, 370,000 shares at November 30, 2018 and May 31, 2018, respectively
(5,714
)
 
(5,714
)
Accumulated other comprehensive loss
(1,250
)
 
(952
)
Total Stockholders’ Equity
549,563

 
542,595

Total Liabilities and Stockholders' Equity
$
783,960

 
$
705,472

The accompanying notes are an integral part of these consolidated financial statements.

5

Table of Contents

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands of dollars)
 
Six Months Ended
 
Nov 30, 2018
 
Nov 30, 2017
Cash flows from operating activities:
 
 
 
Net income
$
1,671

 
$
214

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
12,291

 
11,677

Stock based compensation
4,741

 
3,763

Change in fair value of contingent consideration
256

 
187

Deferred income taxes
495

 
(106
)
Change in accounts receivable allowances
(75
)
 
280

Fixed and intangible asset impairments and disposals
12

 
8

Other
(17
)
 
(557
)
Changes in operating assets and liabilities:

 

Accounts receivable
(3,068
)
 
2,299

Inventories
(955
)
 
598

Prepaid expenses and other
(1,183
)
 
(703
)
Accounts payable, accrued and other liabilities
(10,082
)
 
(4,459
)
Net cash provided by operating activities
4,086

 
13,201

Cash flows from investing activities:
 
 
 
Additions to property, plant and equipment
(1,416
)
 
(1,222
)
Cash paid for acquisitions
(84,920
)
 

Net cash used in investing activities
(86,336
)
 
(1,222
)
Cash flows from financing activities:
 
 
 
Proceeds from issuance of and borrowings on long-term debt
55,000

 

Repayment of long-term debt
(2,500
)
 
(2,500
)
Payment of acquisition related contingent consideration
(2,100
)
 
(9,500
)
Proceeds from exercise of stock options and employee stock purchase plan
854

 
1,738

Net cash provided by (used) in financing activities
51,254

 
(10,262
)
Effect of exchange rate changes on cash and cash equivalents
(280
)
 
595

(Decrease) increase in cash and cash equivalents
(31,276
)
 
2,312

Cash and cash equivalents at beginning of period
74,096

 
47,544

Cash and cash equivalents at end of period
$
42,820

 
$
49,856

Supplemental disclosure of non-cash investing and financing activities:
 
 
 
 
 
 
 
Change in accounts payable for property and equipment
$
(19
)
 
$
98

Fair value of contingent consideration for acquisitions
25,100

 

Fair value of acquisition consideration included in accrued expenses and other long-term liabilities
4,863

 

The accompanying notes are an integral part of these consolidated financial statements.

6

Table of Contents

AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(unaudited)
(in thousands of dollars, except share data)

 
 
Common Stock
 
Additional
paid in
capital
 
Retained earnings
 
Accumulated
other
comprehensive
loss
 
Treasury Stock
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
Total
Balance at May 31, 2018
37,594,493

 
$
370

 
$
543,762

 
$
5,129

 
$
(952
)
 
(370,000
)
 
$
(5,714
)
 
$
542,595

Net loss
 
 
 
 
 
 
$
(469
)
 
 
 
 
 
 
 
(469
)
Exercise of stock options
71,336

 
1

 
607

 
 
 
 
 
 
 
 
 
608

Issuance/Cancellation of restricted stock units
149,446

 
 
 
(460
)
 
 
 
 
 
 
 
 
 
(460
)
Issuance/Cancellation of performance share units
5,235

 
 
 
 
 
 
 
 
 
 
 
 
 

Purchases of common stock under ESPP
40,547

 
1

 
556

 
 
 
 
 
 
 
 
 
557

Stock-based compensation
 
 
 
 
2,150

 
 
 
 
 
 
 
 
 
2,150

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
(92
)
 
 
 
 
 
(92
)
Balance at August 31, 2018
37,861,057

 
$
372

 
$
546,615

 
$
4,660

 
$
(1,044
)
 
(370,000
)
 
$
(5,714
)
 
$
544,889

Net income
 
 
 
 
 
 
2,140

 
 
 
 
 
 
 
2,140

Exercise of stock options
10,571

 


 
149

 
 
 
 
 
 
 
 
 
149

Issuance/Cancellation of restricted stock units
3,901

 


 


 
 
 
 
 
 
 
 
 

Issuance/Cancellation of performance share units


 
 
 
 
 
 
 
 
 
 
 
 
 

Purchases of common stock under ESPP


 


 


 
 
 
 
 
 
 
 
 

Stock-based compensation
 
 
 
 
2,591

 
 
 
 
 
 
 
 
 
2,591

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
(206
)
 
 
 
 
 
(206
)
Balance at November 30, 2018
37,875,529

 
$
372

 
$
549,355

 
$
6,800

 
$
(1,250
)
 
(370,000
)
 
$
(5,714
)
 
$
549,563
























7

Table of Contents


AngioDynamics, Inc. and Subsidiaries
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - continued
(unaudited)
(in thousands of dollars, except share data)

 
Common Stock
 
Additional
paid in
capital
 
Retained earnings (deficit)
 
Accumulated
other
comprehensive
loss
 
Treasury Stock
 
 
 
Shares
 
Amount
 
 
 
Shares
 
Amount
 
Total
Balance at May 31, 2017
37,210,091

 
$
367

 
$
532,705

 
$
(11,007
)
 
$
(1,324
)
 
(370,000
)
 
$
(5,714
)
 
$
515,027

Net loss
 
 
 
 
 
 
(35
)
 
 
 
 
 
 
 
(35
)
Adjustment from the adoption of ASU 2016-09
 
 
 
 
199

 
(199
)
 
 
 
 
 
 
 

Exercise of stock options
17,897

 
 
 
89

 
 
 
 
 
 
 
 
 
89

Issuance/Cancellation of restricted stock units
119,098

 
1

 
 
 
 
 
 
 
 
 
 
 
1

Issuance/Cancellation of performance share units
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Purchases of common stock under ESPP
50,900

 
 
 
722

 
 
 
 
 
 
 
 
 
722

Stock-based compensation
 
 
 
 
1,797

 
 
 
 
 
 
 
 
 
1,797

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
283

 
 
 
 
 
283

Balance at August 31, 2017
37,397,986

 
$
368

 
$
535,512

 
$
(11,241
)
 
$
(1,041
)
 
(370,000
)
 
$
(5,714
)
 
$
517,884

Net income
 
 
 
 
 
 
249

 
 
 
 
 
 
 
249

Adjustment from the adoption of ASU 2016-09
 
 
 
 


 
 
 
 
 
 
 
 
 

Exercise of stock options
78,211

 
1

 
925

 
 
 
 
 
 
 
 
 
926

Issuance/Cancellation of restricted stock units
5,478

 
 
 
 
 
 
 
 
 
 
 
 
 

Issuance/Cancellation of performance share units
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Purchases of common stock under ESPP
 
 
 
 


 
 
 
 
 
 
 
 
 

Stock-based compensation
 
 
 
 
1,966

 
 
 
 
 
 
 
 
 
1,966

Other comprehensive loss, net of tax
 
 
 
 
 
 
 
 
195

 
 
 
 
 
195

Balance at November 30, 2017
37,481,675

 
$
369

 
$
538,403

 
$
(10,992
)
 
$
(846
)
 
(370,000
)
 
$
(5,714
)
 
$
521,220


The accompanying notes are an integral part of these consolidated financial statements.

8

Table of Contents

AngioDynamics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. CONSOLIDATED FINANCIAL STATEMENTS
The consolidated balance sheet as of November 30, 2018, the consolidated statement of stockholders’ equity for the three and six months ended November 30, 2018 and 2017, and the consolidated statements of income, consolidated statements of comprehensive income (loss) for the three and six months ended November 30, 2018 and 2017, and consolidated statements of cash flows for the six months ended November 30, 2018 and 2017 have been prepared by us and are unaudited. The consolidated balance sheet as of May 31, 2018 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2018 (and for all periods presented) have been made.
The unaudited interim consolidated financial statements for the three and six months ended November 30, 2018 and 2017 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
2. ACQUISITIONS

RadiaDyne Acquisition

On September 21, 2018, the Company acquired RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes. The aggregate purchase price of $75.0 million included an upfront payment of $47.9 million, contingent consideration with an estimated fair value of $22.3 million, an indemnification holdback of $4.6 million and a purchase price holdback of $0.2 million. The fair value of $22.3 million in contingent consideration is comprised of $16.5 million for the revenue milestones and $5.8 million for the technical milestones. The $4.6 million indemnification holdback is recorded in other long-term liabilities and the $0.2 million purchase price holdback is recorded in accrued liabilities.
This acquisition expands the Company’s growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies.
The Company accounted for the RadiaDyne acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of RadiaDyne products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the RadiaDyne acquisition, which are included in acquisition, restructuring and other expenses, net in the accompanying consolidated statements of income, were approximately $1.6 million. The following table summarizes the preliminary aggregate purchase price allocated to the net assets acquired:

9

Table of Contents

(in thousands)
 
Sep 21, 2018
Assets acquired
 
 
Accounts receivable
 
$
900

Inventory
 
732

Prepaid and other current assets
 
98

Property, plant and equipment
 
133

Intangible assets:
 
 
RadiaDyne trademark
 
400

OarTrac trademark
 
200

RadiaDyne legacy product technology
 
1,500

OarTrac product technology
 
16,300

RadiaDyne customer relationships
 
3,700

Goodwill
 
51,482

Total assets acquired
 
$
75,445

Liabilities assumed
 
 
Accounts payable
 
$
352

Accrued expenses
 
106

Total liabilities assumed
 
$
458

Net assets acquired
 
$
74,987



The allocation of the purchase price to the assets acquired and liabilities assumed, including the amount allocated to goodwill, is subject to change within the measurement period (up to one year from the acquisition date) as additional information that existed at the date of the acquisition related to the values of assets acquired and liabilities assumed is obtained.
The values assigned to the RadiaDyne and OarTrac trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademarks are deemed to have a useful life of five to seven years and the product technologies are deemed to have a useful life of seven to ten years. Both are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over fifteen years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
BioSentry Acquisition
On August 14, 2018, the Company acquired the BioSentry product from Surgical Specialties, LLC (“SSC”), for an aggregate purchase price of $39.8 million of which $37.0 million was paid on August 14, 2018 and $2.8 million was recorded as contingent consideration. The contingent consideration liability was recorded at fair value and will be payable to SSC upon fulfillment of certain hydrogel orders.
The Company accounted for the BioSentry acquisition under the acquisition method of accounting for business combinations. Accordingly, the cost to acquire the assets was allocated to the underlying net assets in proportion to estimates of their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. Goodwill is deductible for income tax purposes.
The Company has not disclosed the amount of revenue and earnings for sales of BioSentry products since acquisition, nor proforma information, because these amounts are not significant to the Company's financial statements. Acquisition-related costs associated with the BioSentry acquisition, which are included in acquisition, restructuring and other expenses, net in the accompanying consolidated statements of income, were approximately $1.0 million. The following table summarizes the

10

Table of Contents

preliminary aggregate purchase price allocated to the net assets acquired:

 
Preliminary allocation
 
Adjustments (1)
 
Revised allocation
(in thousands)
 
 
 
 
 
 
Inventory
 
$
50

 
$

 
$
50

Property, plant and equipment
 
10

 

 
10

Intangible assets:
 
 
 
 
 
 
    BioSentry trademark
 
1,700

 
800

 
2,500

    BioSentry product technology
 
13,800

 
7,100

 
20,900

    Customer relationships
 
2,500

 
(300
)
 
2,200

Goodwill
 
21,740

 
(7,600
)
 
14,140

Net assets acquired
 
$
39,800

 
$

 
$
39,800

(1) Measurement period adjustments are recognized on a prospective basis in the period of change, instead of restating prior periods. There was no impact to reported earnings in connection with these measurement period adjustments for the periods presented. Amounts represent adjustments to the preliminary purchase price allocation first presented in the Company's Quarterly Report on Form 10-Q for the quarter ended August 31, 2018 resulting from revising the Company's purchase price allocation for this acquisition.
The allocation of the purchase price to the assets acquired and liabilities assumed, including the amount allocated to goodwill, is subject to change within the measurement period (up to one year from the acquisition date) as additional information that existed at the date of the acquisition related to the values of assets acquired and liabilities assumed is obtained.
The values assigned to the BioSentry trademark and product technologies were derived using the relief-from-royalties method under the income approach. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value. The trademark and product technologies are deemed to have a fifteen year useful life and are amortized on a straight-line basis over their useful life.
The value assigned to customer relationships was derived using the multi-period excess earnings method under the income approach. This approach estimates the excess earnings generated over the lives of the customers that existed as of the acquisition date and discounts such earnings to present value. Customer relationships are amortized on a straight-line basis over ten years.
The goodwill arising from the acquisition consists largely of synergies and economies of scale the Company hopes to achieve from combining the acquired assets with the Company's current operations.
3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Adoption of ASC Topic 606 "Revenue from Contracts with Customers"
The Company adopted ASC 606, Revenue from Contracts with Customers on June 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for fiscal 2019 reflect the application of ASC 606 guidance while the reported results for fiscal 2018 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”). For discussion of the Company’s accounting policy for revenue recognition under ASC 605, refer to Item 8 of the Annual Report on Form 10-K for the year ended May 31, 2018. The adoption of ASC 606 did not have an impact on the Company’s consolidated balance sheet, results of operations, equity or cash flows as of the adoption date or for the periods presented, other than the enhanced disclosures included in this footnote.
Revenue Recognition

Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

11

Table of Contents

The Company has one primary revenue stream which is the sales of its products.
Disaggregation of Revenue
The following tables summarize net product revenue by Global Business Unit ("GBU") and geography for the three and six months ended November 30, 2018:
 
Three months ended November 30, 2018
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies 

$
42,826

 
$
9,668

 
$
52,494

Vascular Access
20,081

 
3,642

 
23,723

Oncology
8,976

 
6,310

 
15,286

Total
$
71,883

 
$
19,620

 
$
91,503

 
Six months ended November 30, 2018
(in thousands)
United States
 
International
 
Total
Net sales
 
 
 
 
 
Vascular Interventions & Therapies 

$
84,864

 
$
17,624

 
$
102,488

Vascular Access
40,528

 
6,985

 
47,513

Oncology
14,175

 
12,667

 
26,842

Total
$
139,567

 
$
37,276

 
$
176,843


Net Product Revenue
The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use. The Company sells its products to its distribution partners and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses.
Contracts and Performance Obligations
The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.
Transaction Price and Allocation to Performance Obligations
Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method. As such, revenue is recorded net of rebates, returns and other deductions.
If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately.




12

Table of Contents

Revenue Recognition
Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the contractual shipping terms of a contract.
In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer.
The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers.
Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.
Variable Consideration
Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a current liability.
Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes a liability for such amounts, which is included in accrued expenses in the accompanying condensed consolidated balance sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes and administrative fees the Company is required to pay to group purchasing organizations.
Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the six months ended November 30, 2018, such product returns were not material.
Contract Balances with Customers
A receivable is recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying condensed consolidated balance sheets.
The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
 
Nov 30, 2018
 
May 31, 2018
(in thousands)
 
 
 
Receivables
$
43,374

 
$
39,401

Contract assets
$

 
$

Contract liabilities
$
1,201

 
$
1,203


During the six months ended November 30, 2018, the Company recognized $0.2 million in revenue that was included in contract liabilities as of the beginning of the period. This was offset by additions to contract liabilities of $0.2 million.



13

Table of Contents

Costs to Obtain or Fulfill a Customer Contract
Prior to the adoption of ASC 606, the Company expensed incremental commissions paid to sales representatives for obtaining product sales. Under ASC 606, the Company recognizes an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.
4. INVENTORIES
Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following:
 
Nov 30, 2018
 
May 31, 2018
(in thousands)
 
Raw materials
$
20,282

 
$
18,678

Work in process
10,125

 
10,808

Finished goods
20,230

 
19,430

Inventories
$
50,637

 
$
48,916



The Company periodically reviews for both obsolescence and loss of value. The Company makes assumptions about the future demand for and market value of the inventory. Based on these assumptions, the Company estimates the amount of obsolete, expiring and slow moving inventory. The total inventory reserve at November 30, 2018 and May 31, 2018 was $5.0 million and $6.1 million, respectively. Of the $5.0 million reserve as of November 30, 2018, $0.4 million relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017 and $0.7 million relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018. Of the $6.1 million reserve as of May 31, 2018, $1.6 million relates to the inventory reserve for Acculis inventory as a result of the recall announced in the fourth quarter of fiscal year 2017 and $0.7 million relates to a specific reserve related to the termination of an agreement with a Japanese distributor in the second quarter of fiscal year 2018.

5. GOODWILL AND INTANGIBLE ASSETS

Intangible assets other than goodwill are amortized over their estimated useful lives on either a straight-line basis or proportionately to the benefit being realized. Useful lives range from two to eighteen years. The Company periodically reviews the estimated useful lives of its intangible assets and reviews such assets or asset groups for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or asset groups may not be recoverable. If an intangible asset or asset group is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.

Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination.

The changes in the carrying amount of goodwill for the six months ended November 30, 2018 were as follows:

(in thousands)
 
Goodwill balance at May 31, 2018
$
361,252

Additions for BioSentry acquisition (Note 2)
14,140

Additions for RadiaDyne acquisition (Note 2)
51,482

Goodwill balance at November 30, 2018
$
426,874




14

Table of Contents

The Company's annual testing for impairment of goodwill was completed as of December 31, 2017. The Company operates as a single operating segment with one reporting unit and consequently evaluates goodwill for impairment based on an evaluation of the fair value of the Company as a whole. The Company determines the fair value of the reporting unit based on the market valuation approach and concluded that it was not more-likely-than-not that the fair value of the Company's reporting unit was less than its carrying value.

Even though the Company determined that there was no goodwill impairment as of December 31, 2017, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2018. The Company continued to assess for potential impairment through November 30, 2018 and noted no events that would be considered a triggering event.
Intangible assets consisted of the following:
 
Nov 30, 2018
 
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
(in thousands)
 
Product technologies
$
185,872

 
$
(74,415
)
 
$
111,457

Customer relationships
62,284

 
(25,252
)
 
37,032

Trademarks
31,500

 
(13,085
)
 
18,415

Licenses
5,752

 
(4,697
)
 
1,055

Distributor relationships
1,250

 
(503
)
 
747

 
$
286,658

 
$
(117,952
)
 
$
168,706

 
May 31, 2018
 
Gross
carrying
value
 
Accumulated
amortization
 
Net carrying
value
(in thousands)
 
Product technologies
$
147,175

 
$
(68,880
)
 
$
78,295

Customer relationships
56,428

 
(23,237
)
 
33,191

Trademarks
28,400

 
(11,809
)
 
16,591

Licenses
5,752

 
(4,357
)
 
1,395

Distributor relationships
1,250

 
(412
)
 
838

 
$
239,005

 
$
(108,695
)
 
$
130,310



Amortization expense for the three months ended November 30, 2018 and 2017 was $5.2 million and $4.1 million, respectively. Amortization expense for the six months ended November 30, 2018 and 2017 was $9.3 million and $8.2 million, respectively.

Expected future amortization expense related to the intangible assets is as follows:
(in thousands)

Remainder of 2019
$
10,277

2020
18,963

2021
17,804

2022
16,919

2023
16,468

2024 and thereafter
88,275


$
168,706




15

Table of Contents

6. ACCRUED LIABILITIES
Accrued liabilities consisted of the following: 
 
Nov 30, 2018
 
May 31, 2018
(in thousands)
 
Payroll and related expenses
$
9,624

 
$
10,235

Royalties
1,522

 
1,537

Accrued severance
1,092

 
1,940

Sales and franchise taxes
1,165

 
683

Outside services
1,357

 
2,396

Litigation matters

 
12,500

Other
6,512

 
5,135

 
$
21,272

 
$
34,426



7. LONG TERM DEBT

On November 7, 2016, the Company entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and JPMorgan Chase Bank, N.A., Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.
The Credit Agreement provides for a $100.0 million senior secured term loan facility (“Term Loan”) and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).
On November 7, 2016, the Company borrowed $100.0 million under the Term Loan and approximately $16.5 million under the Revolving Facility to repay the balance of $116.5 million under the former credit agreement. As of November 30, 2018 and May 31, 2018 the carrying value of long-term debt approximates its fair market value.
The interest rate on the Term Loan at November 30, 2018 was 3.80%.

The Company was in compliance with the Credit Agreement covenants as of November 30, 2018.

The Company's maturities of principal obligations under the Credit Agreement are as follows, as of November 30, 2018:
(in thousands)

Remainder of 2019
$
2,500

2020
7,500

2021
11,250

2022
68,750

     Total term loan
90,000

Revolving facility (1)
55,000

     Total debt
145,000

Less: Unamortized debt issuance costs
(734
)
     Total
144,266

Less: Current portion of long-term debt
(5,000
)
     Total long-term debt, net
$
139,266



(1) The revolving facility is due in fiscal year 2022.

16

Table of Contents

8. INCOME TAXES
The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur.  The estimated annual effective tax rate prior to discrete items was 26.3% in the second quarter of fiscal 2019, as compared to 59.8% for the same period in fiscal 2018. In fiscal 2019, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes and state taxes.
On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”). The Tax Reform Act is significant and has wide-ranging effects.
The Company is still studying all of the ramifications of the Tax Reform Act, but expects the primary material impact of the Act to be the remeasurement of the Company’s naked credit deferred tax liability, which was recorded in fiscal 2018 as a result of the reduction in U.S. corporate tax rates from 35% to 21%. The Tax Reform Act imposes a one-time transition tax on the deemed repatriation of post-1986 undistributed foreign subsidiaries’ earnings. Based on the information available as of December 31, 2017, the Company estimated undistributed foreign earnings in fiscal 2018. The taxable income arising from this deemed repatriation is expected to result in the utilization of net operating loss carryforwards and other tax credits, offset by changes in the valuation allowance, resulting in no net impact to tax expense. No changes have been made to these estimates and the Company expects to complete its accounting for these items within the prescribed measurement period.
The Tax Reform Act also creates a new requirement that certain income earned by foreign subsidiaries (“GILTI”), must be included in U.S. gross income. The FASB allows an accounting policy election of either recognizing deferred taxes for temporary differences expected to reverse as GILTI in future years or recognizing such taxes as a current period expense when incurred. The Company has not yet adopted an accounting policy.
The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Evidence the Company considered included its history of net operating losses, which resulted in the Company recording a full valuation allowance for its deferred tax assets in fiscal 2016, except the naked credit deferred tax liability.
Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of November 30, 2018. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.
9. SHARE-BASED COMPENSATION

The Company has two stock-based compensation plans that provide for the issuance of up to approximately 11.3 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to the Company's employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to the Company's employees, directors and other service providers. The Company also has an employee stock purchase plan.

For the three months ended November 30, 2018 and 2017, share-based compensation expense was $2.6 million and $2.0 million, respectively. For the six months ended November 30, 2018 and 2017, share-based compensation expense was $4.7 million and $3.8 million, respectively.

During the six months ended November 30, 2018 and 2017, the Company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company's shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.

In the first six months of fiscal year 2019, the Company granted market-based performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the Company's common stock

17

Table of Contents

relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of the Company's shares on the date of grant and use a Monte Carlo simulation model.

As of November 30, 2018, there was $18.0 million of unrecognized compensation expense related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The Company has sufficient shares to satisfy expected share-based payment arrangements.

10. EARNINGS PER SHARE
Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive.
The following table reconciles basic to diluted weighted-average shares outstanding for the three and six months ended November 30, 2018 and 2017 (in thousands):
 
 
Three Months Ended
 
Six Months Ended
(in thousands)
Nov 30, 2018
 
Nov 30, 2017
 
Nov 30, 2018
 
Nov 30, 2017
Basic
37,500

 
37,066

 
37,411

 
36,983

Effect of dilutive securities
617

 
317

 
720

 
339

Diluted
38,117

 
37,383

 
38,131

 
37,322

 
 
 
 
 
 
 
 
Securities excluded as their inclusion would be anti-dilutive
2,384

 
1,124

 
2,354

 
1,095



11. SEGMENT AND GEOGRAPHIC INFORMATION

The Company considers the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. The Company's chief operating decision maker, the President and Chief Executive Officer (CEO), evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
The table below summarizes net sales by Global Business Unit: 
 
Three Months Ended
 
Six Months Ended
(in thousands)
Nov 30, 2018
 
Nov 30, 2017
 
Nov 30, 2018
 
Nov 30, 2017
Net sales
 
 
 
 
 
 
 
Vascular Interventions & Therapies 

$
52,494

 
$
51,368

 
$
102,488

 
$
101,234

Vascular Access
23,723

 
22,574

 
47,513

 
45,812

Oncology
15,286

 
12,764

 
26,842

 
25,071

Total
$
91,503

 
$
86,706

 
$
176,843

 
$
172,117


The table below presents net sales by geographic area based on external customer location: